TY - JOUR
T1 - Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers
AU - Stankevic, Evelina
AU - Israelsen, Mads
AU - Juel, Helene Baek
AU - Madsen, Anne Lundager
AU - Ängquist, Lars
AU - Aldiss, Peter Stuart Jacob
AU - Torp, Nikolaj
AU - Johansen, Stine
AU - Hansen, Camilla Dalby
AU - Hansen, Johanne Kragh
AU - Thorhauge, Katrine Holtz
AU - Lindvig, Katrine Prier
AU - Madsen, Bjørn Staehr
AU - Sulek, Karolina
AU - Legido-Quigley, Cristina
AU - Thiele, Maja Sofie
AU - Krag, Aleksander
AU - Hansen, Torben
N1 - Liver International© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
PY - 2023/12
Y1 - 2023/12
N2 - BACKGROUND: Frequent binge drinking is a known contributor to alcohol-related harm, but its impact on systemic and hepatic inflammation is not fully understood. We hypothesize that changes in immune markers play a central role in adverse effects of acute alcohol intake, especially in patients with early liver disease.AIM: To investigate the effects of acute alcohol intoxication on inflammation-related markers in hepatic and systemic venous plasma in people with alcohol-related liver disease (ArLD), non-alcoholic fatty liver disease (NAFLD) and healthy controls.METHODS: Thirty-eight participants (13 with ArLD, 15 with NAFLD and 10 healthy controls) received 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube. Seventy-two inflammation-related markers were quantified in plasma from hepatic and systemic venous blood, at baseline, 60 and 180 min after intervention.RESULTS: Alcohol intervention altered the levels of 31 of 72 and 14 of 72 markers in the systemic and hepatic circulation. All changes observed in the hepatic circulation were also identified in the systemic circulation after 180 min. Only FGF21 and IL6 were increased after alcohol intervention, while the remaining 29 markers decreased. Differences in response to acute alcohol between the groups were observed for 8 markers, and FGF21 response was blunted in individuals with steatosis.CONCLUSION: Acute alcohol intoxication induced changes in multiple inflammation-related markers, implicated in alcohol metabolism and hepatocellular damage. Differences identified between marker response to binge drinking in ArLD, NAFLD and healthy controls may provide important clues to disease mechanisms and potential targets for treatment.CLINICAL TRIAL NUMBER: NCT03018990.
AB - BACKGROUND: Frequent binge drinking is a known contributor to alcohol-related harm, but its impact on systemic and hepatic inflammation is not fully understood. We hypothesize that changes in immune markers play a central role in adverse effects of acute alcohol intake, especially in patients with early liver disease.AIM: To investigate the effects of acute alcohol intoxication on inflammation-related markers in hepatic and systemic venous plasma in people with alcohol-related liver disease (ArLD), non-alcoholic fatty liver disease (NAFLD) and healthy controls.METHODS: Thirty-eight participants (13 with ArLD, 15 with NAFLD and 10 healthy controls) received 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube. Seventy-two inflammation-related markers were quantified in plasma from hepatic and systemic venous blood, at baseline, 60 and 180 min after intervention.RESULTS: Alcohol intervention altered the levels of 31 of 72 and 14 of 72 markers in the systemic and hepatic circulation. All changes observed in the hepatic circulation were also identified in the systemic circulation after 180 min. Only FGF21 and IL6 were increased after alcohol intervention, while the remaining 29 markers decreased. Differences in response to acute alcohol between the groups were observed for 8 markers, and FGF21 response was blunted in individuals with steatosis.CONCLUSION: Acute alcohol intoxication induced changes in multiple inflammation-related markers, implicated in alcohol metabolism and hepatocellular damage. Differences identified between marker response to binge drinking in ArLD, NAFLD and healthy controls may provide important clues to disease mechanisms and potential targets for treatment.CLINICAL TRIAL NUMBER: NCT03018990.
KW - alcohol
KW - inflammation
KW - liver disease
KW - proteomics
KW - Alcoholic Intoxication/complications
KW - Humans
KW - Non-alcoholic Fatty Liver Disease
KW - Binge Drinking/complications
KW - Ethanol/adverse effects
KW - Inflammation
U2 - 10.1111/liv.15692
DO - 10.1111/liv.15692
M3 - Journal article
C2 - 37592403
SN - 1478-3223
VL - 43
SP - 2680
EP - 2691
JO - Liver International
JF - Liver International
IS - 12
ER -